Literature DB >> 11689773

Hypertension and renal dysfunction in long-term liver transplant recipients.

T A Gonwa1.   

Abstract

1. A 10-year survival rate of 60% or greater after orthotopic liver transplantation (OLT) is expected. 2. Renal dysfunction is common after OLT. 3. Patients without early renal dysfunction after OLT are at low risk for long-term renal dysfunction. 4. Hypertension occurs in greater than 50% of long-term survivors. 5. Immunosuppressive protocols must be adjusted early to avoid long-term complications.

Entities:  

Mesh：

Year:  2001        PMID： 11689773     DOI： 10.1053/jlts.2001.28511

Source DB:  PubMed          Journal:  Liver Transpl        ISSN： 1527-6465            Impact factor:   5.799


  8 in total

Review 1.  Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review.

Authors:  Dong-Wei Xu; Ping Wan; Qiang Xia
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

2.  Risk factors for end-stage kidney disease after pediatric liver transplantation.

Authors:  R L Ruebner; P P Reese; M R Denburg; E B Rand; P L Abt; S L Furth
Journal:  Am J Transplant       Date:  2012-09-20       Impact factor: 8.086

3.  Sirolimus monotherapy versus sirolimus in combination with steroids and/or MMF for immunosuppression after liver transplantation.

Authors:  Anurag Maheshwari; Michael S Torbenson; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

4.  Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience.

Authors:  Εvangelos Cholongitas; Ioannis Goulis; Eleni Theocharidou; Nikolaos Antoniadis; Ioannis Fouzas; Dimitrios Giakoustidis; George Imvrios; Olga Giouleme; Vasilios Papanikolaou; Evangelos Akriviadis; Themistoklis Vasiliadis
Journal:  Hepatol Int       Date:  2013-12-28       Impact factor: 6.047

5.  Liver cell adenoma and liver cell adenomatosis.

Authors:  Ludger Barthelmes; Iain S Tait
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

6.  The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors.

Authors:  Patrick Lam; Atsushi Yoshida; Kimberly Brown; Marwan Abouljoud; Iman Bajjoka; Fadi Dagher; Dilip K Moonka
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

Review 7.  Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study.

Authors:  Giuseppina Pisano; Anna L Fracanzani; Lucio Caccamo; Maria F Donato; Silvia Fargion
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

8.  Everolimus with or without mycophenolate mofetil in a liver transplantation setting: a single-center experience.

Authors:  Εvangelos Cholongitas; Ioannis Goulis; Eleni Theocharidou; Nikolaos Antoniadis; Ioannis Fouzas; George Imvrios; Olga Giouleme; Aliki Angelaki; Themistoklis Vasiliadis; Vasilios Papanikolaou; Evangelos Akriviadis
Journal:  Ann Gastroenterol       Date:  2018-05-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.